LIXTE Doubles Ovarian Cancer Trial as LB-100 Targets Treatment-Resistant Tumors
March 30, 2026 — LIXTE Biotechnology expands LB-100 clinical trial for ovarian clear cell cancer, doubling patient enrollment to test novel combination therapy approach against treatment-resistant tumors.